

**Table 1: Status of Recently Submitted, Licensed, and Recommended Vaccines**

Click on disease names for current Red Book® recommendations.

General Recommendations on Immunization from ACIP - [cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm](http://cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm)

Vaccine	Manufacturer	BLA submitted to FDA	BLA age indications**	FDA licensure	Status of AAP/CDC recommendations***
<a href="#">Hib (Hiberix®)</a>	GlaxoSmithKline (GSK)	Mar-2009	Booster dose in children 15 months through 4 years of age	Licensed 19-Aug-09	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5836a5.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5836a5.htm</a>
<a href="#">HPV4 (GARDASIL®)</a>	Merck	Dec-2005	Females 9 through 26 years of age	Licensed 8-Jun-06	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr56e312a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr56e312a1.htm</a>
		sBLA	Males 9 through 26 years of age	Licensed 16-Oct-09	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5920a5.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5920a5.htm</a> AAP: <a href="http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2011-3865">pediatrics.aappublications.org/cgi/doi/10.1542/peds.2011-3865</a>
		sBLA	Prevention of anal cancer in males and females nine through 26 years of age	Licensed 22-Dec-10	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm">cdc.gov/mmwr/preview/mmwrhtml/mm6050a3.htm</a>
<a href="#">HPV2 (Cervarix™)</a>	GSK	Mar-2007	Females 10 through 25 years of age	Licensed 16-Oct-09	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm</a>
<a href="#">Influenza vaccines - TIV</a>	varies	n/a	See recommendations	varies	AAP: <a href="http://pediatrics.org/cgi/doi/10.1542/peds.2011-2295">pediatrics.org/cgi/doi/10.1542/peds.2011-2295</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm60e0818a1.htm">cdc.gov/mmwr/preview/mmwrhtml/mm60e0818a1.htm</a>
<a href="#">Influenza – LAIV-T (FluMist®)</a>	MedImmune	sBLA	24 months through 49 years of age	Licensed 19-Sep-07	CDC Seasonal: <a href="http://cdc.gov/flu">cdc.gov/flu</a>
		sBLA	Quadrivalent vaccine including 2 B strains	To be reviewed	Red Book Online Influenza Resource Page: <a href="http://aapredbook.org/flu">aapredbook.org/flu</a> Pending review
<a href="#">Influenza – Intradermal (Fluzone®)</a>	sanofi pasteur	New administration route	18 through 64 years of age	Licensed 9-May-11	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm60e0818a1.htm">cdc.gov/mmwr/preview/mmwrhtml/mm60e0818a1.htm</a>
<a href="#">MCV4 (Menactra®)</a>	sanofi pasteur	Dec-2003	11 through 55 years of age	Licensed 14-Jan-05	AAP: <a href="http://aappolicy.aappublications.org/cgi/content/full/pediatrics:116/2/496">aappolicy.aappublications.org/cgi/content/full/pediatrics:116/2/496</a>
			2 through 10 years of age	Licensed 17-Oct-07	CDC Menactra: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5407a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5407a1.htm</a>
			9 through 23 months of age	Licensed 22-Apr-11	CDC Menveo: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5909a5.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5909a5.htm</a> CDC Update: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm6030a3.htm">cdc.gov/mmwr/preview/mmwrhtml/mm6030a3.htm</a>
<a href="#">MCV4 (Menveo™)</a>	Novartis	Apr-2010	11 through 55 years of age	Licensed 19-Feb-10	Recommendations for children at prolonged risk: see <a href="#">Table 3</a> .
			2 through 10 years of age	Licensed 28-Jan-11	CDC Menactra Recommendations for children under 2 years of age: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm6040a4.htm">cdc.gov/mmwr/preview/mmwrhtml/mm6040a4.htm</a>
			2, 4, 6, 12 through 16 months of age	To be reviewed	Pending review
<a href="#">MenCY-Hib (MenHibrix™)</a>	GSK	2009	2, 4, 6 and 12 months of age	To be reviewed	Pending FDA licensure
<a href="#">MMRV (ProQuad®)</a>	Merck	Aug-2004	Same as for MMR for dose 1 or dose 2: 12 months through 12 years of age	Licensed 6-Sep-05	AAP: <a href="http://aappolicy.aappublications.org/cgi/content/full/pediatrics:120/1/221">aappolicy.aappublications.org/cgi/content/full/pediatrics:120/1/221</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5447a4.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5447a4.htm</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5903a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5903a1.htm</a>
<a href="#">PCV13 (Prevnar 13®)</a>	Wyeth	Mar-2009	2 months through 71 months of age	Licensed 25-Feb-10	AAP: <a href="http://aappolicy.aappublications.org/cgi/content/full/pediatrics:126/1/186">aappolicy.aappublications.org/cgi/content/full/pediatrics:126/1/186</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5909a2.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5909a2.htm</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm</a>
<a href="#">Rotavirus (ROTATEQ®)</a>	Merck	Apr-2005	2, 4, and 6 months of age	Licensed 3-Feb-06	Recommendations for adults: see <a href="#">Table 3</a> .
<a href="#">Rotavirus (ROTARIX®)</a>	GSK	Jun-2007	2 and 4 months of age	Licensed 3-Apr-08	AAP: <a href="http://aappolicy.aappublications.org/cgi/content/full/pediatrics:123/5/1412">aappolicy.aappublications.org/cgi/content/full/pediatrics:123/5/1412</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5802a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5802a1.htm</a> Recommendations for contraindication for SCID: see <a href="#">Table 3</a> .
<a href="#">Tdap (ADACEL™)</a>	sanofi pasteur	Aug-2004	11 through 64 years of age	Licensed 10-Jun-05	AAP: <a href="http://aappolicy.aappublications.org/cgi/content/full/pediatrics:117/3/965">aappolicy.aappublications.org/cgi/content/full/pediatrics:117/3/965</a> AAP Update: <a href="http://aappolicy.aappublications.org/cgi/content/full/pediatrics:128/4/809">aappolicy.aappublications.org/cgi/content/full/pediatrics:128/4/809</a>
<a href="#">Tdap (BOOSTRIX®)</a>	GSK	Jul-2004	10 through 18 years of age	Licensed 3-May-05	CDC Adolescent: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5503a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5503a1.htm</a> CDC Update: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm6001a4.htm">cdc.gov/mmwr/preview/mmwrhtml/mm6001a4.htm</a> CDC Pregnancy: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5704a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5704a1.htm</a> ACIP Provisional: <a href="http://cdc.gov/vaccines/recs/provisional/downloads/pregnant-Tdap-use.pdf">cdc.gov/vaccines/recs/provisional/downloads/pregnant-Tdap-use.pdf</a>
		sBLA	19 through 64 years of age	Licensed 4-Dec-08	CDC Adacel for health care personnel: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5517a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5517a1.htm</a>
		sBLA	Greater than or equal to 65 years of age	Licensed 8-Jul-11	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5814a5.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5814a5.htm</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm6037a3.htm">cdc.gov/mmwr/preview/mmwrhtml/mm6037a3.htm</a>

Table Updated: 2/27/12

Table available on Red Book Online: [www.aapredbook.org/news/vaccstatus.dtl](http://www.aapredbook.org/news/vaccstatus.dtl)

BLA = biologics license application, VRBPAC = Vaccines and Related Biological Products Advisory Committee, FDA = Food and Drug Administration, AAP = American Academy of Pediatrics, ACIP = Advisory Committee on Immunization Practices, DTaP = Diphtheria, Tetanus and Pertussis, Hib = Haemophilus influenzae b, HPV = human papillomavirus vaccine, IPV = Inactivated Poliovirus Vaccine, LAIV-T = Live attenuated influenza vaccine-trivalent, MCV4 = Meningococcal conjugate vaccine, MMRV = measles, mumps, rubella, varicella, PCV13 = Pneumococcal 13-valent conjugate, PPSV23 = 23-Valent Pneumococcal Polysaccharide Vaccine, Tdap = Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, adsorbed  
\*Information from vaccine manufacturers, from ACIP meetings and from AAP  
\*\*Age licensure can change following FDA review; not final until package insert approved  
\*\*\*ACIP recommendations do not become official until approved by the CDC Director and Department of HHS and publication in MMWR



Current Recommended Immunization Schedules: [0-6 Years](#) | [7-18 Years](#) | [Catch-up Schedule](#) | [Adult](#)  
Vaccine supply shortages may result in changes to recommendations. Please consult [cdc.gov/vaccines/vac-gen/shortages/default.htm](http://cdc.gov/vaccines/vac-gen/shortages/default.htm)

**Table 2: Status of Older Vaccine Licensure and Recommendations**

Vaccine	Manufacturer	BLA submitted to FDA	BLA age indications**	FDA licensure	Status of AAP/CDC recommendations***
<a href="#">DTaP-IPV (KINRIX)</a>	GlaxoSmithKline (GSK)	Jun-2007	4 through 6 years of age	Licensed 24-Jun-08	AAP: <a href="http://aappolicy.aappublications.org/cgi/content/full/pediatrics:128/4/805">aappolicy.aappublications.org/cgi/content/full/pediatrics:128/4/805</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5739a4.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5739a4.htm</a>
<a href="#">DTaP-IPV/Hib (PENTACEL™)</a>	sanofi pasteur	Jul-2005	2, 4, 6, and 15 through 18 months of age	Licensed 20-Jun-08	AAP: <a href="http://aappolicy.aappublications.org/cgi/content/full/pediatrics:128/4/805">aappolicy.aappublications.org/cgi/content/full/pediatrics:128/4/805</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5739a5.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5739a5.htm</a>
<a href="#">Hepatitis A (VAQTA®)</a>	Merck	sBLA	Greater than or equal to 12 months of age	Licensed 11-Aug-05	AAP: <a href="http://aappolicy.aappublications.org/cgi/content/full/pediatrics:120/1/189">aappolicy.aappublications.org/cgi/content/full/pediatrics:120/1/189</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.htm</a>
<a href="#">Hepatitis A (HAVRIX®)</a>	GlaxoSmithKline (GSK)	sBLA	Greater than or equal to 12 months of age	Licensed 17-Oct-05	CDC for post-exposure and for international travelers: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5641a3.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5641a3.htm</a>
<a href="#">Varicella virus second dose (Varivax®)</a>	Merck	sBLA: second dose	12 months to 12 years of age (3 month minimum interval)	Licensed 5-Apr-05	AAP: <a href="http://aappolicy.aappublications.org/cgi/content/full/pediatrics:120/1/221">aappolicy.aappublications.org/cgi/content/full/pediatrics:120/1/221</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm</a>

Table Updated: 2/27/12

**Table 3: Status of Recommendations for Vaccine Use in Special Circumstances or in Adults, or Changes in Recommended Vaccine Use**

Vaccine	Indications**	Date of Recommendation	Web site
<a href="#">Anthrax AVA</a>	People at risk of or already exposed to <i>Bacillus anthracis</i> spores	July 2010	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm</a>
<a href="#">Hepatitis A and Hepatitis B (TWINRIX®)</a>	Greater than or equal to 18 years of age: 0, 7, and 21 through 30 days; 12 month booster	Mar 2007	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5640a5.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5640a5.htm</a>
<a href="#">Hepatitis A</a>	International adoptees	Sep 2009	AAP: <a href="http://aappolicy.aappublications.org/cgi/content/abstract/pediatrics:128/4/803">aappolicy.aappublications.org/cgi/content/abstract/pediatrics:128/4/803</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5836a4.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5836a4.htm</a>
<a href="#">Herpes zoster vaccine (ZOSTAVAX®)</a>	Greater than or equal to 60 years of age 50 through 59 years of age	May 2006	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr57e0515a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr57e0515a1.htm</a>
		Mar 2011	Pending review
<a href="#">Influenza (Afluria)</a>	Greater than or equal to 9 years of age	Aug 2010	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5931a4.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5931a4.htm</a>
<a href="#">Influenza, high dose</a>	65 years of age and older	Apr 2010	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5916a2.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5916a2.htm</a>
<a href="#">Japanese Encephalitis (IXIARO)</a>	Greater than or equal to 17 years of age Booster dose	Mar 2010	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5901a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5901a1.htm</a> May 2011 Update: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm6020a6.htm">cdc.gov/mmwr/preview/mmwrhtml/mm6020a6.htm</a>
		Feb 2011	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm6020a5.htm">cdc.gov/mmwr/preview/mmwrhtml/mm6020a5.htm</a>
<a href="#">MCV4 (Menactra)</a>	2 through 55 years of age, reimmunize people at prolonged risk of meningococcal disease	Sep 2009	AAP: <a href="http://aapnews.aappublications.org/cgi/reprint/28/12/14-a.pdf">aapnews.aappublications.org/cgi/reprint/28/12/14-a.pdf</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5648a4.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5648a4.htm</a>
		Jan 2011	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5717a4.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5717a4.htm</a> CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm</a> CDC Update: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm">cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm</a>
<a href="#">MCV4 (Menveo)</a>	2 through 55 years of age, reimmunize people at prolonged risk of meningococcal disease	Jan 2011	CDC Update: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm">cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm</a>
<a href="#">MMR</a>	Evidence of immunity requirement for healthcare personnel	Jun 2009	ACIP Provisional: <a href="http://cdc.gov/vaccines/recs/provisional/downloads/mmr-evidence-immunity-Aug2009-508.pdf">cdc.gov/vaccines/recs/provisional/downloads/mmr-evidence-immunity-Aug2009-508.pdf</a>
<a href="#">PPSV23</a>	All adults aged 65 years and older and those adults aged 19--64 years with underlying medical conditions that put them at greater risk for serious pneumococcal infection.	Sep 2010	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5934a3.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5934a3.htm</a>
<a href="#">PCV13</a>	Greater than or equal to 50 years of age	To be reviewed	Pending FDA licensure
<a href="#">Polio</a>	Final dose administered on or after 4 <sup>th</sup> birthday and at least 6 months following previous dose	Aug 2009	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5830a3.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5830a3.htm</a>
<a href="#">Rabies HDCV or PCECV</a>	4-dose vaccination regimen for postexposure prophylaxis	Mar 2010	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5902a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5902a1.htm</a>
<a href="#">RV5 and RV1</a>	Addition of severe combined immune deficiency as a contraindication for administration of rotavirus vaccine	Feb 2010	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/mm5922a3.htm">cdc.gov/mmwr/preview/mmwrhtml/mm5922a3.htm</a>
<a href="#">Tdap</a>	All healthcare personnel	Apr 2011	ACIP: <a href="http://cdc.gov/vaccines/recs/provisional/downloads/use-of-Tdap-in-hcp.pdf">cdc.gov/vaccines/recs/provisional/downloads/use-of-Tdap-in-hcp.pdf</a>
<a href="#">Yellow Fever</a>	Persons greater than or equal to 9 months of age traveling to or living in areas at risk for yellow fever transmission in South America and Africa.	Oct 2009	CDC: <a href="http://cdc.gov/mmwr/preview/mmwrhtml/rr5907a1.htm">cdc.gov/mmwr/preview/mmwrhtml/rr5907a1.htm</a>

Table Updated: 2/27/12